New triple-drug combo aims to improve leukemia treatment without standard chemo
Disease control
Recruiting now
This study tests a combination of three drugs (olutasidenib, venetoclax, and azacitidine) in people with a specific genetic form of acute myeloid leukemia (IDH1 mutation). The goal is to see if this combo is safer and works better than standard intensive chemotherapy. About 16 ad…
Phase: PHASE2 • Sponsor: Justin Watts, MD • Aim: Disease control
Last updated May 22, 2026 14:04 UTC